Stockwinners Market Radar for August 26, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:30 EDT Bilibili falls over 6% tp $45.60 per share after Q2 results, Q3 guidance

19:11 EDT Brink's announces $50M acclerated share repurchase - The Brink's Company announced that it has entered into an accelerated share repurchase agreement with J.P. Morgan Chase Bank, N.A, to repurchase $50M of the company's common stock. Brink's will execute the ASR under the $250M share repurchase authorization announced on February 6, 2020, which had been temporarily suspended due to uncertainties associated with the Covid-19 pandemic.

18:52 EDT Abbott's $5 15-minute COVID-19 antigen test gets FDA EUA - The company states: "Abbott announced that the FDA has issued Emergency Use Authorization, or EUA, for its BinaxNOW COVID-19 Ag Card rapid test for detection of COVID-19 infection. Abbott will sell this test for $5. It is highly portable, affordable and provides results in 15 minutes. BinaxNOW uses proven Abbott lateral flow technology, making it a reliable and familiar format for frequent mass testing through their healthcare provider. With no equipment required, the device will be an important tool to manage risk by quickly identifying infectious people so they don't spread the disease to others. Abbott will also launch a complementary mobile app for iPhone and Android devices named NAVICA. This first-of-its-kind app, available at no charge, will allow people who test negative to display a temporary digital health pass that is renewed each time a person is tested through their healthcare provider together with the date of the test result. Organizations will be able to view and verify the information on a mobile device to facilitate entry into facilities along with hand-washing, social distancing, enhanced cleaning and mask-wearing. In data submitted to the FDA from a clinical study conducted by Abbott with several leading U.S. research universities, the BinaxNOW COVID-19 Ag Card demonstrated sensitivity of 97.1% and specificity of 98.5% in patients suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset."

18:16 EDT Amazon.com director sells 750 shares of common stock - Amazon.com CEO of Worldwide Consumer business, Jeffrey Wilke, sold 750 shares of common stock on August 24th in a transaction size of $2.5M.

18:04 EDT China Distance Education CEO says Q3 revenue was within guidance range - hengdong Zhu, CEO of CDEL, said, "In the third quarter of fiscal 2020, we reported net revenue of $50.7 million, within our guidance range. During the onset of the COVID-19 pandemic, in order to support our students across China with high-quality online professional education at a time when offline classes were suspended, we provided free online courses to students in Hubei province and significant discounts for certain online exam preparation courses to students outside Hubei. Our socially responsive actions resulted in a surge in enrollment in our second fiscal quarter as previously disclosed, effectively pulling forward the demand for our courses and thus dampening enrollment and cash receipts growth in our third fiscal quarter. We believe in the long-term growth prospects of online professional education in China, and expect online education will continue to transform how knowledge is delivered and how students learn. We remain committed to serving students with our high-quality courseware and compelling online educational solutions during this challenging time. We are confident that our comprehensive lifelong learning ecosystem will enable us to reach a broad and growing student audience, and extend convenience, flexibility and engagement to their learning experience."

17:57 EDT BorgWarner falls almost 2% after SEC settles charges against company - Shares of BorgWarner are down 72c per share, or 1.73% in after-hours trading to $40.81 per share after the SEC news release. BorgWarner shares ended the regular session at $41.53 per share up 1.30% on the day.

17:46 EDT Salesforce CEO says to keep open mind about future of work - In a Bloomberg interview, CEO Benioff says has not made a decision about work from home policy as he has not been through a pandemic before. Says pandemic causes you as CEO to reassess every part of your business. Says Facebook (FB) is addictive and needs to be regulated by the government.

17:25 EDT GrubHub CEO sells 4.9K shares of common stock - In a regulatory filing, GrubHub disclosed that its CEO Matthew Maloney sold 4,886 shares of common stock on August 24th in a total transaction size of $376.4K.

17:15 EDT Kennedy Wilson CEO acquires 75,000 common shares - In a regulatory filing, Kennedy-Wilson CEO William J. McMorrow disclosed the acquisition of 75,000 common shares of the company on August 26 at a price of $14.07 per share.

17:09 EDT Goldfield Corp announces passing of Chairman and CEO John Sottile - The Goldfield Corporation announced with great sadness the passing today of its Chairman and CEO John Sottile. The company's Board of Directors and management, on behalf of all employees and stockholders, mourn the passing of Sottile and express our deepest condolences to the Sottile family. Sottile joined the company in 1971. He managed two of the company's principal subsidiaries, Tropicana Pools and Harlan Fuel Company, before becoming President and CEO of the company in 1983 and Chairman of the Board in 1998.

17:08 EDT Allison Transmission's electric hybrid propulsion selected by IndyGo - Allison Transmission will supply IndyGo, the Indianapolis Transportation Corporation, its next generation electric hybrid propulsion solutions for transit buses as part of a 27-unit bus procurement. The Allison H 40 EP will be paired with the Cummins B6.7 in 24 of the 27 Gillig buses. In addition, Allison's new electric hybrid propulsion system, eGen Flex, will be integrated into three of IndyGo's new buses. The eGen Flex Max specified by IndyGo will enable pure electric operation for up to 10 miles on any route, at any time, without capital infrastructure investment in charging stations.

17:01 EDT Hilltop Holdings names Clare Graca as Chief Administrative Officer - Hilltop Securities announced the addition of Clare Graca as Chief Administrative Officer and Manal Keen as Senior Vice President of Finance and Strategy for Wealth Management.

16:46 EDT Rollins names Gary Rollins as board Chair - The Rollins board announced appointments to further strengthen the company's Executive Leadership. Gary W. Rollins has been elevated by the company's Board of Directors to the Rollins Board Chairmanship. John Wilson, currently Rollins President and COO, will be promoted to the company's Vice Chairman. Jerry Gahlhoff will be promoted to President/COO of Rollins.

16:34 EDT Kilroy Realty raises quarterly dividend 3.1% to 50c per share - Kilroy Realty Corporation announced that its board of directors declared a regular quarterly cash dividend of 50c per common share payable on October 14, 2020 to stockholders of record on September 30, 2020. The dividend is equivalent to an annual rate of $2.00 per share and is a 3.1% increase from the previous annualized dividend level of $1.94 per share.

16:32 EDT AllianceBernstein names Ali Dibadj as new CFO effective February of 2021 - AllianceBernstein announced that Ali Dibadj, in addition to his current role as Head of Strategy at AB, will assume the title of CFO. This change will take effect February 2021. Mr. Dibadj joined AB in 2006 as a senior research analyst for Bernstein Research. In 2019, he co-led AB's Strategy Committee to help senior management chart the strategic vision and course of action for the firm. Mr. Dibadj was appointed Head of Finance and Strategy in March 2020.

16:30 EDT Princess Cruises extends pause of operations in Australia through December 12 - Due to the continued progression of COVID-19 and related decisions of various governments, health authorities, and airlines regarding travel restrictions, Princess Cruises is extending its pause in cruise operations in Australia through December 12, 2020 which includes cruises throughout Australia and New Zealand. Guests who have paid in full on these cancelled voyages will receive a refundable Future Cruise Credit (FCC) equivalent to 100% of the cruise fare paid plus an additional non-refundable bonus FCC equal to 25% of the cruise fare paid. To receive the above FCCs, no action is required by the guest or their travel advisor.

16:27 EDT Williams-Sonoma backs long-term revenue guidance of up mid-high single digits - Sees "operating margin expansion" vs. prior forecast of "operating Income growth in line with revenue growth, driving Operating Margin stability".

16:20 EDT Williams-Sonoma falls over 11% to $87.98 per share after Q2 earnings

16:18 EDT Riot Blockchain purchases 5,100 next generation Bitmain S19 Pro Antminers - Riot Blockchain continues its commitment to bitcoin mining with the new purchase of 5,100 next generation Bitmain S19 Pro Antminers for $11.2M from BitmainTech PTE. LTD., scheduled for receipt and deployment starting in February 2021. In line with Riot's goal of miner expansion, and together with Bitmain's increased production capacity during early 2021, this purchase and the recently disclosed order of 8,000 S19 Pros, results in 13,100 miners scheduled to be received and deployed in the first half of 2021. As a result of this order size, the company was able to secure advantageous pricing per unit on both this order and the recent order of 8,000 S19 Pro miners. The additional volume discount provided by Bitmain reduced the previously announced purchase price for the 8,000 S19 Pros from $17.7M to $17.5M. As far as the company is aware, no other publicly traded bitcoin mining company has disclosed a hashing capacity exceeding 2 EH/s. Riot anticipates that based upon current factors, Riot would achieve positive cash flow in late 2020 when the Company's total hashing capacity is expected to reach 566 PH/s. With the full deployment of these 13,100 S19 Pros, Riot is expected to more than triple that hash rate capacity by the end of June 2021.

16:10 EDT GrowGeneration rallies 7% to $15 after Stifel puts $22 target on shares

16:08 EDT Box surges 14% to $22 per share after Q2 results

15:05 EDT Walmart slashes 230M tons of emissions since 2017 - In a blog post, Walmart said that, with the help of its suppliers, it has cut 230M metric tons of cumulative emissions since its Project Gigaton program began in 2017. Gigaton is the company's global effort to avoid 1B metric tons of emissions by 2030. "More then 2,300 suppliers have signed on to Project Gigaton," the company said. "Suppliers reported 136 million metric tons (MMT) of avoided emissions, which brings us to 230 MMT of cumulative avoided emissions since the program began in 2017." Reference Link

14:06 EDT Activision's 'Call of Duty: Black Ops Cold War' out November 13, 2020 - According to a listing on Activision Blizzard's Battle.net marketplace, "Call of Duty: Black Ops Cold War will come out on November 13, 2020. Reference Link

14:02 EDT Epic says new 'Fortnite' update will not release on iOS, macOS on August 27 - In an update on its #FreeFortnite page on its official website, Epic Games said that Apple (AAPL) is blocking Fortnite updates and new installs on the App Store, and has said they will terminate Epic's ability to develop "Fortnite" for Apple devices. As a result, Fortnite's newly released Chapter 2 - Season 4 update (v14.00), will not release on iOS and macOS on August 27, Epic said. Investors in Epic include Tencent (TCEHY), KKR (KKR), Disney (DIS), and Sony (SNE). The Verge's Jay Peters noted that the move effectively splits "Fortnite" into two different games. Reference Link

13:03 EDT Ball Aerospace selected for Space RCO Tactical GC3 contract - Ball Aerospace (BLL), teamed with Booz Allen Hamilton (BAH), was awarded a contract by the Space Rapid Capabilities Office to serve as the prime system integrator for the SpRCO Ground Command, Control and Communications system. GC3 will integrate into and help enable the larger tactical command and control enterprise for the United States Space Force. The program will develop and deliver updated and enhanced satellite operations capabilities that enable continuous modernization by maximizing automation, flexibility and commonality.

12:36 EDT Urban Tea clarifies effectiveness date for 1 for 10 reverse share split - Urban Tea clarified its press release dated August 25, 2020. On August 25, 2020, the company had announced that a 1 for 10 reverse split of its ordinary shares is expected to become effective on or around August 26, 2020. The company would like to clarify that the Reverse Split is expected to become effective on August 27, 2020. As previously announced, upon the effectiveness of the Reverse Split, Urban Tea shareholders will receive one new ordinary share of Urban Tea for every ten shares they hold. Urban Tea's ordinary shares is expected to begin trading on a split-adjusted basis when the market opens on August 27, 2020.

12:09 EDT Facebook says Apple changes to 'disproportionately affect' Audience Network - Facebook said in a blog post, "In June, Apple announced iOS 14 updates that, among other changes, require apps to ask users for permission to collect and share data using Apple's device identifier. Given the impact the policy will have on businesses' ability to market themselves and monetize through ads, we're sharing how we're addressing iOS 14 changes and providing recommendations to help our partners prepare, while developers await more details on this policy. First, we will not collect the identifier for advertisers (IDFA) on our own apps on iOS 14 devices. We believe this approach provides as much certainty and stability that we can provide our partners at this time. We may revisit this decision as Apple offers more guidance. Additionally, we will remind users that they have a choice about how their information is used on Facebook and about our Off-Facebook Activity feature, which allows them to see a summary of the off-Facebook app and website activity businesses send to Facebook and disconnect it from their accounts...We expect these changes will disproportionately affect Audience Network given its heavy dependence on app advertising. Like all ad networks on iOS 14, advertiser ability to accurately target and measure their campaigns on Audience Network will be impacted, and as a result publishers should expect their ability to effectively monetize on Audience Network to decrease. Ultimately, despite our best efforts, Apple's updates may render Audience Network so ineffective on iOS 14 that it may not make sense to offer it on iOS 14. We expect less impact to our own advertising business, and we're committed to supporting advertisers and publishers through these updates."

12:00 EDT K12 falls -11.1% - K12 is down -11.1%, or -$4.82 to $38.75.

12:00 EDT Garrett Motion falls -42.0% - Garrett Motion is down -42.0%, or -$2.89 to $3.99.

12:00 EDT Salesforce rises 26.0% - Salesforce is up 26.0%, or $56.10 to $272.15.

11:58 EDT 'Branded third-party experience,' Movie Tickets By Atom, launches in Snapchat - Social movie ticketing app Atom Tickets announces the launch of Movie Tickets By Atom, "a branded third-party experience" within Snapchat (SNAP). "The Snap Mini experience is now available to millions of Snapchatters interested in watching movie trailers, buying movie tickets and sharing movie plans with friends all without leaving Snapchat... As theaters start to re-open across the country, Atom conducted a new survey and based on over 16,000 digital moviegoer respondents, 74% said they are ready to return to theaters within the next month...Snap Minis are third-party experiences that live inside of Snapchat and can be accessed through Snapchat's Chat interface. By using Movie Tickets By Atom, the movie-loving millennial and Gen Z Snapchat audience can bypass the group texts and money requests that come with organizing a traditional movie night with friends. Following a ticket purchase, Snapchatters can share a post containing movie event details with individual friends, a group or to a Snap Story. The post will include a link for friends to get their own tickets to join in and choose seats nearby," the company said in a statement. The Movie Tickets By Atom Mini will support ticketing for all of Atom's exhibitor partners including: AMC Theatres (AMC), Cinemark (CNK), Harkins Theatres, National Amusements' Showcase Cinemas, CMX Cinemas, Landmark in Cinemas of Canada, Studio Movie Grill, Malco Theatres, Landmark Theatres, ArcLight Cinemas, and Larry H. Miller Megaplex Theatres, among others.

11:37 EDT Aon, Willis Towers Watson announce shareholder approval of proposed combination - Aon (AON) and Willis Towers Watson (WLTW) announced that their respective shareholders voted FOR all proposals at their respective extraordinary general meetings and at the special meeting of Willis Towers Watson shareholders ordered by the High Court of Ireland. Aon and Willis Towers Watson shareholders approved all of the proposals necessary to complete the previously announced combination of Aon and Willis Towers Watson. The combination, which remains subject to customary regulatory and other closing conditions, is expected to close in the first half of 2021. Upon the closing of the combination, Willis Towers Watson shareholders will receive 1.08 Aon shares in exchange for each Willis Towers Watson share they held immediately prior to the closing.

11:15 EDT Aegion awarded $6M contract for cathodic protection services in West Texas - Aegion Corporation announced that its subsidiary, Corrpro Companies, Inc., has been awarded a contract valued at more than $6M to deliver a comprehensive package of cathodic protection services to prevent corrosion on new midstream pipeline construction in West Texas.

11:09 EDT Toll Brothers expects to keep raising prices

11:08 EDT Toll Brothers: Strong demand has continued so far in August

11:07 EDT Toll Brothers: May's contracts down 21%, June's up 76%, July's up 31% y/y - Comments taken from Q3 earnings conference call.

10:18 EDT Chief of Staff Meadows says 'hopefully we can help the airlines' - White House Chief of Staff Mark Meadows said this morning at an event hosted by Politico, "If Congress is not going to work, this president is going to get to work and solve some problems. Hopefully we can help the airlines and keep some of those employees from being furloughed." Meadows, according to Bloomberg, noted assistance would require another legislative package but that the White House was "looking at other executive actions" and planned "a few" additional unilateral stimulus measures. Publicly traded companies in the airlines space include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Southwest (LUV), Spirit Airlines (SAVE) and United Airlines (UAL).

10:03 EDT Citius Pharmaceuticals announces license agreement with MDACC - Citius Pharmaceuticals announced that it has expanded the intellectual property associated with its global license agreement with the MD Anderson Cancer Center. Through this license agreement, Citius is developing Mino-Wrap, which is a novel approach to reducing post-mastectomy infections associated with the use of a tissue expander. The United States Patent and Trademark Office has issued patent 10,434,221 B2 and patent application publication US 2019/0388591 A1, both continuations of the initial patent for "Antimicrobial Wraps for Medical Implants". The intellectual property expansion was granted to The Board of Regents of The University of Texas System on behalf of The University of Texas M. D. Anderson Cancer Center and enhances the design and use of Mino-Wrap. The Company is also currently developing Mino-Lok, an antibiotic lock treatment for catheter-related bloodstream infections, in collaboration with MDACC. Mino-Lok is in phase 3 development.

09:47 EDT Phoenix Tree falls -7.2% - Phoenix Tree is down -7.2%, or -59c to $7.56.

09:47 EDT Garrett Motion falls -40.8% - Garrett Motion is down -40.8%, or -$2.81 to $4.07.

09:47 EDT Salesforce rises 17.0% - Salesforce is up 17.0%, or $36.78 to $252.83.

09:43 EDT Catalyst and KYE challenging Health Canada issuance of NOC for Ruzurgi - Catalyst Pharmaceuticals and marketing partner KYE Pharmaceuticals announced the filing of a proceeding in Canadian Federal Court challenging Health Canada's issuance of a Notice of Compliance, or NOC, on August 10 for Medunik's New Drug Submission for the drug Ruzurgi for the treatment of Lambert-Eaton Myasthenic Syndrome despite the fact that Catalyst's Firdapse was issued an NOC on July 31, 2020 and was granted data protection as an "innovative drug" as it was the first amifampridine product to be approved in Canada. The proceeding seeks judicial review of Health Canada's decision to issue an NOC for Ruzurgi as "incorrect and unreasonable," the companies said. "Innovative drugs, not previously approved in Canada, go through a rigorous drug approval process in Canada. A sponsor must submit clinical and nonclinical safety, tolerability, and efficacy data, to demonstrate the safety and efficacy of the drug. In exchange for that effort, and as an incentive to do that, Health Canada regulations are supposed to prevent other pharmaceutical companies from being able to use the innovator's (in this case Catalyst's) data as a basis for approval for eight years from the date of the Notice of Compliance. In Firdapse's case, Health Canada only did so for ten days. We are compelled to bring this application to preserve the specialized regulatory framework for new chemical entities, and the future of drug innovation in Canada," added Patrick McEnany, Chairman and CEO of Catalyst.

09:34 EDT Nevada reports July statewide gaming win down 26.16% to $756.79M - Nevada reports July Las Vegas Strip gaming win down 39.19% to $330.09M. Publicly traded companies in the gambling space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn National (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN).

09:23 EDT Revive submits IRB approval for Phase 3 trial protocol for bucillamine - Revive Therapeutics announced that following the U.S. Food & Drug Administration approval to proceed with the Company's Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19, the Company has submitted its clinical trial protocol for independent Institutional Review Board approval. Additionally, the Company is exploring the FDA Expanded Access Program, also referred to as the Compassionate Use Program, that can provide access to the Company's investigational drug, Bucillamine, for people who meet the protocol criteria of the COVID-19 study. Revive expects to have patients enrolled in September 2020.

09:18 EDT Chicken Soup for the Soul announces new content for Crackle Plus - Chicken Soup for the Soul Entertainment announced the upcoming content releases for Crackle for September. Crackle is available in the U.S. and can be accessed on 26 devices and services including Amazon FireTV, RokuTV, Apple TV, Smart TVs, gaming consoles, Plex, on iOS and Android mobile devices and on desktops at Crackle.com. Crackle is also available in approximately 500,000 hotel rooms in the Marriott Bonvoy chain.

09:18 EDT Muscle Maker adds two locations in Philadelphia to ghost kitchen model - Muscle Maker announced that it has signed an agreement to open two more ghost kitchens in Philadelphia, PA. The company will now operate seven ghost kitchen facilities in two major cities across the U.S. The company plans to begin construction immediately for an anticipated early October opening. Similar to Chicago, the new Philadelphia ghost kitchens will showcase menus from Muscle Maker Grill and Healthy Joe's. Guests can order healthier for you dishes from either of the concepts through third party delivery platforms providing ease of ordering and the option for contactless delivery. Ordering platforms include: DoorDash, GrubHub, UberEats, Postmates, ChowNow and Caviar. As the demand for delivery increases due to social distancing, many restaurant concepts are looking toward ghost kitchens to expand quickly while meeting the growing need for fast options.

09:17 EDT Alkaline Water says Dot Foods to offer line of Alkaline88, A88 Infused - The Alkaline Water Company announced that Dot Foods will offer the entire line of Alkaline88, A88 Infused, and aluminum bottles to its 4,300 customers nationwide by September 21, 2020.

09:13 EDT Stereotaxis announces publication on study using robotic technology - Stereotaxis announced a pioneering publication in the prestigious Journal of the American College of Cardiology on the use of Stereotaxis' robotic technology to treat pulmonary hypertension. Dr. Alexander Romanov and colleagues at the National Medical Research Center in Novosibirsk, Russia led an investigator-initiated 50-patient, prospective, randomized, blinded, sham-controlled study of pulmonary artery denervation using Robotic Magnetic Navigation for patients with chronic thromboembolic pulmonary hypertension after pulmonary endarterectomy. CTEPH is a severe form of pulmonary hypertension caused by blood clots that don't dissolve in the lungs leading to progressive right heart failure. In the study, denervation of the pulmonary arteries was performed using a robotically-navigated ablation catheter. Patients receiving this treatment compared favorably across all efficacy and safety endpoints to those that received a sham procedure and were treated with best pharmaceutical care. At 12 months post-procedure, pulmonary vascular resistance was lower, pulmonary artery pressure was reduced, patients performed better on a 6-minute walk test, and hospitalization due to heart failure was reduced by 86%.

09:12 EDT Change Healthcare acquires PROMETHEUS Analytics - Change Healthcare said in a release, "Change Healthcare announced it has acquired PROMETHEUS Analytics from Altarum. PROMETHEUS Analytics is a leading reimbursement approach based on medical episodes of care, used by payer-provider collaborations nationwide, uniquely providing a fair and realistic blueprint for value-based payments. It includes more than 90 episode of care definitions outlining the entire range of treatment that include all covered services across providers that would typically treat a patient for a single procedure, illness or condition. This transaction supports Change Healthcare's commitment to focus on and invest in core aspects of the business to fuel long-term growth, advance innovation and accelerate the industry's transition to value-based care."

09:10 EDT Wabtec appoints Eric Gebhardt as Chief Technology Officer - Wabtec said in a release, "Wabtec announced the appointment of Eric Gebhardt to Executive Vice President and Chief Technology Officer, effective September 14. In this role, Gebhardt will lead Wabtec's global technology and investment strategy, new product development, and global engineering organization. He comes to this role as former Managing Director of KCK-US, an investment firm focused on the energy, life science, and industrial sectors."

09:09 EDT Agora reports 85.5% customer base growth year-over-year - Agora announced steep growth across its customer base in Q2 driven by increased demand for real-time engagement technology. Agora grew its customer base by 85.5% year-over-year as of June 2020. Real-time engagement technology rapidly reached widespread adoption as companies shifted critical business functions to the virtual world.

09:05 EDT Natera's Signatera test receives CE mark - Natera has received the CE mark for the Signatera test, a personalized, tumor-informed ctDNA assay optimized for molecular residual disease assessment and treatment monitoring in patients previously diagnosed with cancer. With the CE mark, Natera can now make Signatera available to clinics and hospital systems throughout Europe to support patient management and clinical research.

09:03 EDT Verizon signs new renewable energy purchase agreements - Verizon Communications announced that it has entered into four more long-term renewable energy purchase agreements totaling more than 450 megawatts of renewable energy capacity as part of its commitment to be carbon neutral in its operations by 2035. These agreements, which are virtual power purchase agreements, will help finance the re-powering of wind energy facilities and the construction of new solar facilities. Verizon entered into two REPAs with Brookfield Renewable for an aggregate of up to 160 MW of capacity at two wind energy facilities that are being repowered. The wind energy facilities are located in New York where Verizon has significant energy usage, and the repowered facilities are expected to be fully operational in 2021. The agreements have 12-year terms and generally are expected to be financially settled. Verizon also entered into two REPAs with First Solar for an aggregate of up to 296 MW of capacity from two solar facilities that are under development in the PJM Interconnection regional market and that First Solar intends to power using its lowest carbon footprint solar modules. The agreements with First Solar have 15-year terms from the commencement of each facility's entry into commercial operations, which is expected to occur in late 2022. The agreements are generally expected to be financially settled.

09:01 EDT H&R Block joins Catalyst CEO Champions for Change - H&R Block announces it has joined the Catalyst CEO Champions for Change pledge to increase the representation of women, including women of color, in its senior leadership and board positions. H&R Block joins more than 60 other leading global companies and CEOs that are committing to advance women and share data with Catalyst on the representation of women in their workplaces so collective progress can be tracked, analyzed and reported, with the goal of inspiring other organizations by their progress. The Catalyst pledge includes a commitment to: Accelerate progress in the representation of women, including women of color, in executive/senior level positions over five years. Maintain or accelerate the representation of women, including women of color, on the Company's Board of Directors over five years. Strengthen the pipeline of women through an annual review of internal diagnostics and leverage leading practices to address any identified issues. Benchmark and track inclusion and improve the culture of inclusion within the organization. Share key representation metrics with Catalyst for benchmarking and for anonymized reporting of our collective aggregate progress.

08:48 EDT Weyland Tech enters agreement to increase stake in AtozPay, AtozGo to 51% - Weyland Tech has reached a definitive agreement that increases its beneficial stake in PT Weyland Indonesia Perkasa, operator of the AtozGo food delivery service and AtozPay mobile e-wallet, from 31% to 51%. Due to Weyland's historical financial support of WIP totaling $4.5M, the transaction will be completed at no new cost to Weyland. The majority ownership will allow Weyland to consolidate WIP's revenue in future quarters.The transaction is expected to be completed within the next two weeks upon satisfaction of certain transaction requirements.

08:39 EDT Wrap Technologies expands domestic presence with orders from Nevada, Arkansas - Wrap Technologies announced its first purchase orders for BolaWrap products and accessories from agencies in the states of Nevada and Arkansas. Since July 1st, the Company has received initial and repeat purchase orders from law enforcement agencies across 13 states. As a result, more than 215 agencies across 44 states now have BolaWrap devices. Despite a 67 day interruption of BolaWrap training due to COVID-19, Wrap Training Academy has conducted 66% more trainings year-to-date than it did in the entirety of 2019 and 329% more trainings during the months of July and August this year relative to 2019.

08:36 EDT Luna Innovations partners with CETENA, GHT Photonics for smart bridge in Italy - Luna Innovations said in a release, "Luna Innovations announced that it has partnered with CETENA and GHT Photonics to help design, build and implement a full-scale, fiber-optic structural health monitoring system for the recently re-opened Polcevera Viaduct bridge, which is a critical traffic artery for the city of Genoa in northern Italy. The innovative bridge, which is over a kilometer long featuring 19 spans, is equipped with an advanced health monitoring system based on a network of Luna's HYPERION measurement systems and advanced fiber optic sensors installed by Luna's integration partner GHT photonics. The system will monitor the structural response of the bridge, as well as conditions including the number and weight of vehicles, water stagnation, weather and other important variables helpful for bridge monitoring, control and inspection. The sensors installed on the infrastructure will capture the data necessary to create a digital twin of the bridge, that reproduces all the viaduct's physical characteristics, in real time."

08:34 EDT Alimera announces national reimbursement granted for ILUVEN in the Netherlands - Alimera Sciences announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary received an add-on status for the pricing and reimbursement approval for ILUVIEN in the Netherlands from the Ministry of Health, effective September 1, 2020. Pricing and reimbursement approval was sought and secured by Alimera's distribution partner in France and the Benelux region, Horus Pharma. Horus is in the process of reviewing launch plans. ILUVIEN is a sustained release intravitreal implant indicated in Europe for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies and for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

08:22 EDT Brookfield names Mark Carney vice chair, head of ESG, impact fund investing - Brookfield Asset Management announced the appointment of Mark Carney as a Vice Chair and Head of ESG and Impact Fund Investing. He is currently the United Nations Special Envoy for Climate Action and Finance and is a longtime advocate for sustainability, specifically with regard to the management and reduction of climate risks. Mark will expand on Brookfield's existing strengths in ESG investing with the development of a group of funds that will work to combine positive social and environmental outcomes with strong risk-adjusted returns for investors. The funds will make ESG-focused investments that are both capable of delivering measurable outcomes against specific impact goals and consistent with Brookfield's extensive experience investing in high-quality, sustainable assets that form the backbone of the global economy.

08:21 EDT Marathon Patent Group enters LOI to acquire Fastblock Mining - Marathon Patent Group announced it has executed a Letter of Intent to acquire Fastblock Mining for 8,658,009 shares of its Common Stock in a private placement transaction exempt from registration. Once the transaction closes, the Company's cost to mine Bitcoin will decline from $7,400 per Bitcoin to $3,600 per Bitcoin due to the lower than industry-standard electricity cost of $0.0285 per KwH. Marathon will also acquire 3,304 ASIC Miners from Fastblock's customers which will increase our deployed ASIC's from 2,060 to 5,364 Miners and immediately add 208/Ph of Hashing capacity to our current Hashrate of 186/Ph, increasing our current Hashrate to 394/Ph. If all 16,960 ASIC Miners were deployed today, they would produce 1,639/Ph, which at today's Bitcoin price and the network's current Hashrate Difficulty, would produce approximately 16 Bitcoin per day and generate monthly revenue of $4,000,000 per month. With a monthly power cost of $1,127,000, this could result in monthly Gross Profits of more than $2,800,000 per month. The foregoing calculation is based on current Bitcoin prices, and a higher or lower Bitcoin price, would result in higher or lower Gross Profit potential, corresponding directly to the differential in Bitcoin price. Fastblock Mining was established in 2014 by CEO and Co-Founder Bernardo Schucman, an expert in crypto mining. Mr. Schucman has managed the Company's Mining as a Service business and built or managed 20 data centers having mined over 50,000 Bitcoins, audited by BDO Trevisan. Mr. Schucman will stay on with the combined Company and become Head of Mining Operations. Fastblock's executive team, consisting of John Blount and Gustavo Caldeira de Andrada, along with the 14 employees at the Atlanta facility, will continue to work at the Company. The Company will work with Fastblock's management team to immediately begin expansion of the current power capacity in the Atlanta, Georgia facility from of 15MwH to 45MwH. The facility may be expanded up to a maximum of 100MwH of power should the Company's expansion efforts require additional power. The transaction is expected to close by the end of September 2020 upon completion of a Definitive Agreement and meeting customary closing conditions, including due diligence review.

08:18 EDT Garrett Motion down 24% at $5.22 after announcing balance sheet review

08:18 EDT RESAAS, QuestCap enter commercial agreement to sell COVID-19 antibody tests - QuestCap, its wholly-owned subsidiary, Collection Sites, and RESAAS Services are pleased to confirm the companies have entered into an agreement to sell U.S. Food and Drug Administration Emergency Use Authorization COVID-19 Rapid Tests to real estate sales professionals across the United States through RESAAS' global real estate platform. QuestCap and Collection Sites will work with RESAAS exclusively to sell the QuestCap's COVID-19 IgG/IgM Antibody test kits within North America to the real estate sector. The agreement was executed on August 24, 2020 with a one-year term. The companies will share in the revenue generated from all sales.

08:15 EDT Tyme Technologies announces potential new COVID-19 treatment approach - Tyme Technologies announced a potential new approach to treating COVID-19 using a metabolic agent, TYME-19. TYME-19 is a synthetic bile acid, a family of metabolic agents that the company also uses in its anticancer product, TYME-18. The company was able to identify TYME-19 as a potent, well characterized antiviral bile acid and has performed preclinical experiments establishing effectiveness against COVID-19. Bile acids have primarily been used for liver disease; however, they represent a family of cellular regulators across cardiovascular, neurologic and metabolic systems, with some also having antiviral properties. Tyme has partnered with physicians from Massachusetts General Hospital and the Weill Cornell Medical Center to design a trial for recently diagnosed, symptomatic patients. The proof-of-concept trial is expected to start as soon as customary trial site approvals are completed. In preclinical testing, TYME-19 repeatedly prevented COVID-19 viral replication without attributable cytotoxicity to the treated cells. Previous preclinical research has also shown select bile acids like TYME-19 have had broad antiviral activity. TYME-19 is part of a family of metabolic agents called bile acids that have formerly been associated with liver disease but are becoming recognized for their potential utility to treat multiple diseases. Bile acids are regulators for many cellular functions throughout the central nervous, cardiovascular and metabolic systems. Tyme and its collaborating partners at Massachusetts General Hospital and Weill Cornell Medical Center are initiating a proof-of-concept study to evaluate TYME-19 versus placebo in newly diagnosed, symptomatic patients with defined high-risk factors. The trial will measure specific indicators of safety and efficacy, including time to resolution of symptoms, changes in viral load, rate of hospitalization and others. Positive results from the proof-of-concept study could lead to a development program in which TYME-19 is studied as a potential new oral treatment for patients with COVID-19 before they require hospitalization, and/or as prophylaxis for high-risk individuals and front-line workers.

08:11 EDT VBI Vaccines selects two COVID-19 vaccine candidates to take into human study - VBI Vaccines announced data from three preclinical mouse studies conducted to enable selection of optimized clinical candidates for the company's coronavirus program, VBI-2900. As a result of these studies, VBI has selected two vaccine candidates, with the potential to be one-dose vaccines, to take into an adaptive Phase 1/2 human clinical study, expected to begin around year-end, subject to regulatory approval. VBI-2901 is a trivalent pan-coronavirus vaccine candidate expressing the SARS-CoV-2, SARS-CoV and MERS-CoV spike proteins. VBI-2902 is a monovalent vaccine candidate expressing the SARS-CoV-2 spike protein. The objectives of the preclinical studies, which evaluated antibody binding titers and neutralizing antibody titers across a number of vaccine constructs, were to assess the impact of VBI's proprietary enveloped virus-like particle, or eVLP, platform technology vs. recombinant vaccine candidates, differences in the conformation of the spike protein and a variety of adjuvants. After a single dose, VBI's eVLPs expressing a stabilized pre-fusion form of the COVID-19 spike protein elicited a nAb GMT that was 4x higher than the GMT of high-titer convalescent sera, which increased to 64x higher after a second dose. The same eVLPs also induced, after one dose, an Ab binding GMT that was 10x higher than both the GMT of high-titer convalescent sera and the GMT induced with a stabilized pre-fusion recombinant spike protein. A variety of adjuvants tested further improved the induction of nAb titers approximately 5-fold, and promoted strong Th1-type antibody and T cell responses. The trivalent eVLP vaccine construct induced Ab binding titers across COVID-19, SARS, and MERS spike proteins in addition to broadening reactivity to a seasonal human coronavirus not expressed in the vaccine. As part of these studies, convalescent sera from 20 individuals who had contracted and recovered from COVID-19 were collected for comparison, this sera was further grouped according to those who mounted a high-titer, robust response to the infection and those with a low-titer, weaker response. The neutralizing activity in these studies were quanitifed using a plaque reduction neutralization test with the most stringent 90% inhibition threshold, which is considered the standard for measuring antibodies that can neutralize a virus. In August, VBI also entered into an agreement with Therapure Biomanufacturing, an integrated contract development and manufacturing organization, for development and manufacturing services in preparation for production of its coronavirus vaccine candidates. The collaboration with Therapure is expected to enable the initiation of clinical studies by the end of 2020. As part of the agreement, Therapure will manufacture bulk vaccine for use through Phase 2 clinical studies.

08:10 EDT Xebec Adsorption appoints Sara Elford to board of directors - Xebec Adsorption announced that Sara Elford has joined Xebec's Board effective August 25th, 2020. Elford is a current board member of BioSyent Inc. and BQE Water Inc., both are TSX-V listed companies.

08:08 EDT Avid Bioservices selected by Mapp Biopharmaceutical for development of antibody - Avid Bioservices announced that Mapp Biopharmaceutical has contracted Avid to provide process transfer, scale-up and clinical manufacturing services to support one of its development programs for a novel antiviral drug candidate. Avid and Mapp will immediately commence the initial phase of the project.

08:05 EDT ExOne enters metal 3D printing services partnership with Xometry - ExOne said in a release, "ExOne and Xometry announced that they will partner to provide metal 3D printing services. Binder jetting offers Xometry customers a fast and cost-effective way to 3D print metal prototypes and production parts. With binder jetting, an inkjet printhead quickly deposits a bonding agent onto a thin layer of powdered particles -- either metal, sand, ceramics or composites. This process is repeated, layer-by-layer, using a map from a digital design file, until the object is complete. ExOne will be the exclusive provider of binder jetting services in Xometry's recently-launched Digital RFQ Marketplace. ExOne currently 3D prints more than 20 materials, including 316L and 17-4PH stainless steels, Inconel 718 and M2 Tool Steel."

08:03 EDT NV5 Global secures $4M in New Mexico transportation project awards - NV5 Global has been awarded $4M in transportation infrastructure contracts in New Mexico. These projects will provide planning, engineering, surveying, and environmental services to support improvements to roadway infrastructure throughout the state. The City of Albuquerque awarded NV5 a $2.2M contract to provide engineering design, surveying, and environmental services for the widening of Paseo del Norte, one of the busiest roadways connecting Downtown Albuquerque to the city's western suburbs. The project will expand the road to two lanes in each direction, adding capacity to reduce current congestion during peak use hours and preparing for traffic volume that is expected to double by 2040. The New Mexico Department of Transportation selected NV5 for $2M in new projects to support transportation improvements to US 491 and NM 68 roadways. In Shiprock, New Mexico, NV5 will support roadway improvements to US 491, including signals and lighting, drainage systems, a three-span bridge structure, and two large bridge-class culvert structures on a critical transportation corridor in the Navajo Nation. NV5 will provide engineering design, surveying, and construction phase engineering services for NM 68 in Espanola and Alcalde to mitigate congestion and safety concerns on the four-lane highway corridor.

08:02 EDT Esports Entertainment Group signs LOI to acquire the Esports Gaming League - Esports Entertainment Group signed a Letter of Intent to acquire the Esports Gaming League, a UK-based esports company, founded in 2010, serving a rapidly expanding community of gamers in Europe, Middle East, and the Americas. EGL is a B2B-centric provider of live and online events and tournaments where gamers can compete and enjoy a wide range of content relating to esports and video games on a proprietary technology platform with over 350K registered gamers. Services include full turnkey esports events, live broadcast production, game launches, and online branded tournaments. The growing user base and the demographics of EGL's audience provide brand owners and advertisers with an attractive environment to promote their products and services.

07:48 EDT Heat Biologics publishes preclinical COVID-19 vaccine results - Heat Biologics announced publication of preclinical COVID-19 results in bioRxiv. Heat's gp96 based COVID-19 vaccine, or gp96-Ig-S, significantly increases the frequency of systemic and tissue-specific CD8+ T-cells by conferring cellular immunity that is essential against any viral infection, including SARS-CoV-2. It also primes potent effector memory CD8+ T cell responses and tissue resident memory CD8+ T cells localized in lung which are essential in protection against respiratory virus infection. The vaccine elicits an immune response directed against the Spike protein of SARS-CoV-2, generating both helper CD4+ T-cells that aide in antibody production, as well as virus killing cytotoxic CD8+ T cells. It also induces the secretion of cytokines from CD8+ and CD4+ T cells in both the spleen and lungs, while inducing high frequencies of S-protein specific CD8+ T cells in the respiratory airways, the predominant site of viral infection. Studies in COVID-19 patients with moderate or asymptomatic infection indicate that the expansion of memory CD8+ T cells directed at immunodominant epitopes on S protein may be important, including tissue resident CD8+ T cells that localize in high numbers in the lung tissue to protect against infection. The preclinical data demonstrates that Heat's vaccine achieves this objective with tissue resident memory CD8+ T cells that localize in lung tissue. The generation of a durable cellular immune response driven by memory CD8+ T cells may protect against re-infection. Heat's vaccine is designed to prophylactically "train" the immune system to induce this response in patients and should be especially effective in those individuals most prone to severe infection, such as the elderly, individuals with relevant comorbidities or other patients who are immuno-suppressed.

07:42 EDT Dick's Sporting ends Q2 with cash, equivalents of $1.1B - Company is in a strong financial position, ending the quarter with cash and cash equivalents of $1.1B and no outstanding borrowings on its $1.855B revolving credit facility.

07:35 EDT Dick's Sporting jumps 16% to $54.01 after Q2 results beat estimates -

07:34 EDT Dick's Sporting CEO says Q2 'exceptionally strong' - "We had an exceptionally strong Q2 in which we delivered our highest ever quarterly sales and earnings. These results are a testament to the hard work and dedication of our teammates, who reacted quickly to favorable shifts in consumer demand throughout the quarter," said Edward Stack, Chairman and CEO. "During this pandemic, the importance of health and fitness has accelerated and participation in socially distant, outdoor activities has increased. There has also been a greater shift toward athletic and active lifestyle product with people spending more time working and exercising at home. The majority of our assortment sits squarely at the center of these trends, and while mindful of the uncertainty in the current environment, we are in a great lane right now." Lauren Hobart, President, added, "Our Q2 comps were supported by increases in both average ticket and transactions, as well as growth across each of our three primary categories of hardlines, apparel and footwear. By the end of June, we re-opened 100% of our stores to the public, while continuing to prioritize the health and well-being of our teammates and athletes. As our stores re-opened, we saw the power of our industry-leading omni-channel platform. We delivered positive double-digit brick-and-mortar store comps during both June and July, and our eCommerce sales remained very strong, increasing nearly 200% for the quarter. In recognition of our hourly store and distribution center teammates' efforts, which helped make these results possible, we recently announced the 15% pay premium will be extended through the end of the year." Stack concluded, "The favorable shifts in consumer demand that drove our strong comps during Q2 have continued into Q3 but have been partially offset by softness across key back-to-school categories because of the uncertain timing of a return to school and fall team sports. Taken together, through the first three weeks of Q3, our consolidated comp sales have increased 11%, which demonstrates the strength of our diverse category portfolio."

07:32 EDT Eloxx Pharmaceuticals announces two preclinical abstracts for NACFC - Eloxx Pharmaceuticals announced that two abstracts will be presented at the North American Cystic Fibrosis Conference to be held virtually starting on October 7, 2020. The two abstracts will be showcased in the NACFC virtual poster gallery and electronically published as a supplement to Pediatric Pulmonology. These virtual posters will be available to registered attendees on the NACFC online conference platform starting on October 7, 2020. "We are pleased to be presenting additional preclinical study results in cystic fibrosis at the 2020 NACFC virtual conference which demonstrate ELX-02's selectivity for read-through of premature stop codons versus native stop codons and its ability to restore production of functional CFTR in patient-derived organoids," said CEO Gregory Williams. "We are advancing our Phase 2 clinical trials for ELX-02 in cystic fibrosis in Europe, Israel and the U.S., and we believe the data from our preclinical programs substantially de-risk this program. We look forward to reporting top line data from our proof of concept Phase 2 clinical trials as quickly as possible." The details for the two ELX-02 poster presentations are: Poster Session Presentation Title: "ELX-02 Generates Protein Via Premature Stop Codon Read-through Without Inducing Native Stop Codon Read-through Proteins". Poster Session Presentation Title: "CFTR Restoration By ELX-02 Across CF Nonsense Genotypes: Utilizing Patient-Derived Organoids to Survey Responsive Alleles".

07:31 EDT Dick's Sporting reports Q2 SSS up 20.7% - Consolidated same store sales increased 20.7%, even with approximately 15% of the company's stores closed on average. eCommerce sales increased 194%, including Curbside Contactless Pickup. eCommerce penetration for the second quarter of 2020 was approximately 30% of total net sales, compared to approximately 12% during the second quarter of 2019. Second quarter 2019 consolidated same store sales increased 3.2%.

07:25 EDT Rubicon Organics expects to achieve monthly positive cash flow in 1H21 - The company said, "Rubicon Organics is focused on producing premium organic certified cannabis products and developing brands for sale to the Canadian market as well as establishing distribution channels to Germany with the expectation to enter international markets in 2021. The Company has three direct supply agreements with the OCS, BCLDB and AGLC and expects to ramp up product deliveries to these markets as well as to access the Quebec market in 2020. The Company plans to continue to use local distributors in Saskatchewan and Manitoba. Following approval from Health Canada on May 5, 2020 for site amendments that included the use of its land at the Delta Facility for an outdoor grow, the Company has launched a pilot scale outdoor grow and is assessing strain suitability to potentially launch a larger outdoor grow program in 2021 with the most successful outdoor strains. The Company is in the process of installing additional high-performance LED lighting in the final three of its five cultivation compartments to supplement sunlight in winter months. Renovations to the Delta Facility's processing area are also underway to facilitate compliance with EU-GMP requirements thereby providing access to the German market. The Company also continues to work to accelerate certain of its innovation pipeline projects. The Company is determined to achieve positive operating cash flow and profitability. The Company currently expects to achieve positive EBITDA on a monthly basis by year-end 2020 and to achieve monthly positive cash flow from operations in the first half of 2021. The Company expects to refinance debt maturing in 2021 to a long-term mortgage financing facility at lower interest rates and may seek other capital through equity, and debt arrangements. The Company expects to list the common shares and 3,150,000 warrants of the Company on the TSXV in September 2020. The Company is actively working to satisfy certain requirements of the TSXV in accordance with the terms of its conditional approval letter."

07:20 EDT Desktop Metal to become public through business combination with Trine - Desktop Metal, which identifies itself as "a leader in mass production and turnkey additive manufacturing solutions," announced it will become a publicly listed company "in order to accelerate its growth trajectory within the rapidly growing additive manufacturing market and capitalize on the strong secular tailwinds supporting the reshoring of manufacturing and supply chain flexibility." The company has signed a definitive business combination agreement with Trine Acquisition Corp. (TRNE), a special purpose acquisition company led by Leo Hindery, Jr. and HPS Investment Partners, a global credit investment firm with over $60B in assets under management. Upon closing of the transaction, the combined operating company will be named Desktop Metal, Inc. and will continue to be listed on the New York Stock Exchange and trade under the ticker symbol "DM." Pursuant to the transaction, TRNE, which currently holds $300M in cash in trust, will combine with Desktop Metal at an estimated $2.5B pro forma equity value. Assuming no redemptions by TRNE's existing public stockholders, Desktop Metal's existing shareholders will hold approximately 74% of the issued and outstanding shares of common stock immediately following the closing of the business combination. Cash proceeds in connection with the transaction will be funded through a combination of TRNE's cash in trust and a $275M fully committed common stock PIPE at $10.00 per share, including investments from funds and affiliates of Miller Value Partners, XN, Baron Capital Group, Chamath Palihapitiya, JB Straubel, and HPS Investment Partners.

07:19 EDT Medipharm Labs launches sublingual sprays for sale under Avicanna agreement - MediPharm Labs announced its wholly-owned subsidiary, MediPharm Labs Inc., has launched and completed production of a new product format, sublingual sprays, as part of its multi-faceted strategic pharmaceutical manufacturing agreement with Avicanna. Marketed under Avicanna's RHO Phyto medical brand, the RHO Phyto Rapid Act Sprays will be available nationally to Canadian medical patients through the Medical Cannabis by Shoppers online healthcare platform in the coming weeks. RHO Phyto Rapid Act Sprays are optimized for increased absorption and faster onset in comparison to basic MCT sublingual sprays. On May 14, 2020, MediPharm Labs entered a 3-year, multi-faceted agreement with Avicanna involving production, domestic and international distribution and intellectual property licensing that will drive growth for both parties. Under the manufacturing segment of the agreement, MediPharm Labs uses its specialized capabilities to produce Avicanna's advanced RHO Phyto medical cannabis products and Pura Earth dermacosmetic topicals. The RHO Phyto Rapid Act Sprays represent the second Avicanna product format produced at MediPharm Labs GMP-certified facility in Barrie, Ontario. The first was Rho Phyto's Blood Orange flavoured Micro Drops, in both high CBD and medium CBD formula made from full spectrum cannabis distillate. Additional product formats, including topicals, capsules and transdermal patches, are being finalized for production under the contract manufacturing agreement.

07:16 EDT Range Resources publishes updated corporate sustainability report - RANGE RESOURCES announced the publication of an updated Corporate Sustainability Report. The 2020 Corporate Sustainability Report covers a broader and deeper set of topics, with a focus on a material set of issues for the business and key stakeholders, underscoring the Company's commitment to increased transparency around these important initiatives. Emissions Reduction Goals and Performance : Range announced new emissions reductions goals in the updated report. The Company's medium-term goal is to achieve the objective of net zero greenhouse gas emissions by 2025 through continued emissions reductions and the use of carbon offsets associated with reforestation and forest management. As an additional interim goal, Range intends to further reduce GHG emissions intensity relative to 2019 levels by 15 percent by 2025. To achieve these targets, Range continues to invest in new technologies and engineering solutions, implement best-in-class emissions reductions practices and develop improved methods to reliably verify emissions through measurement. These efforts have positioned Range as a leader in emissions reductions amongst peers. Based on third-party data from Rystad Energy, an independent energy research firm, Range is ranked among the lowest in CO2 emissions intensity in a group of 58 global oil and natural gas producers. In addition to the Company's new emissions reduction targets, the report highlights progress Range continues to make towards its broader environmental, social and governance priorities. Strong Governance Culture: Management and oversight of sustainability factors fully integrated into daily operations; Proactive ongoing outreach to shareholders soliciting feedback on ESG efforts; Thirty-three percent of independent directors are female. Health and Safety Leadership: Zero incidents resulting in work restrictions or days away from work experienced by Range employee workforce in 2019; 3,179 hours of safety-related training completed by workforce over past year. Environmental Stewardship: Net Zero GHG Direct Emissions by 2025 through continued emissions reductions and the use of carbon offsets associated with reforestation and forest management, as well as the consideration of all other available and emerging offset methodologies; Continue reducing GHG emissions intensity with interim objective of further reduction of 15 percent by 2025 compared to 2019 GHG emissions intensity levels; Reduced GHG footprint by 47 percent in absolute GHG emissions since 2017; Water management leader: Recycled 147 percent of produced water volume through water sharing program. Community Impact: Contributed over $442,000 to more than 350 non-profit and civic organizations across core operating footprint. Over 700 employee hours volunteered at company-sponsored events and community initiatives.

07:12 EDT B.O.S. Better Online expects to return to net profit in Q3

07:08 EDT Akoustis announces third 5G infrastructure design win - Akoustis Technologies announced that it has been awarded a third design win for 5G small cell network infrastructure XBAW filters from an existing tier-1 customer. The Company expects to enter commercial production in the second half of calendar 2020. This third design win is for 5G band n79 small cell network infrastructure filters and follows Akoustis' recently announced wide bandwidth n77 XBAW filter which has now been qualified in the customer's initial build of 5G small cell base stations. Akoustis completed initial sample shipments earlier in the June quarter and expects to increase shipments during the current quarter. The Company's tier-1 OEM customer has received 5G network infrastructure contract awards from the mobile carriers and plans to ramp volume production of all three 5G small cell base station XBAW filters in the second half of calendar 2020.

07:06 EDT Carrier announces California school district to install 1,500 OptiClean units - Carrier announced that California's Alvord Unified School District will install 1,500 Carrier OptiClean 1,500 cfm dual-mode air scrubber and negative air machines to purify the air in classrooms across its 23 schools. The school district worked with Climatec, a building solutions consultant, to select OptiClean as the solution to enhance indoor air quality and help ensure a healthy indoor environment for its nearly 20,000 students and staff. Carrier is a part of Carrier Global.

07:04 EDT Rocket Pharmaceuticals adds 4 additional clinical trial sites for FA, LAD-I, IMO - Rocket Pharmaceuticals said in a release, "Rocket Pharmaceuticals announces the addition of four additional clinical trial sites across four clinical programs for Fanconi Anemia, or FA, Leukocyte Adhesion Deficiency-I, or LAD-I, Danon Disease and Infantile Malignant Osteopetrosis, or IMO. The newly added centers, which include some of the leading gene therapy research programs in the world, are: Great Ormond Street Hospital, Children's Hospital of Philadelphia, the University of Minnesota and the University of California, Los Angeles."

07:03 EDT Oncolytics doses first patient in Phase 2 study of pelareorep in breast cancer - Oncolytics (ONCY) has dosed the first patient in the company's investigator-sponsored phase 2 study of pelareorep-anti-PD-1 combination therapy in unresectable locally advanced or metastatic triple-negative breast cancer. The study, known as IRENE, is co-sponsored by Oncolytics, the Rutgers Cancer Institute of New Jersey, and Incyte (INCY). Participants in the multi-center study receive pelareorep in combination with Incyte's anti-PD-1 checkpoint inhibitor retifanlimab. The IRENE study builds on prior clinical data showing pelareorep-induced priming of an adaptive immune response in multiple breast cancer subtypes.

06:47 EDT Garrett Motion exploring alternatives for balance sheet restructuring - Garrett Motion announced that, with the assistance of its financial and legal advisors, it is exploring alternatives for addressing its previously disclosed balance sheet concerns. The company stated, "On June 12, 2020, Garrett entered into an amendment to its credit agreement to obtain relief from certain financial covenants, including the consolidated leverage ratio, in light of current and anticipated operating conditions. However, as disclosed in Garrett's quarterly report on Form 10-Q for the three months ended June 30, 2020, notwithstanding the relief provided by the credit agreement amendment, Garrett's leverage ratio remains high and we expect will remain so for at least the next several quarters. Garrett's leveraged capital structure poses significant challenges to its overall strategic and financial flexibility and may impair its ability to gain or hold market share in the highly competitive automotive supply market, thereby putting Garrett at a meaningful disadvantage relative to its peers. In addition, Garrett's high leverage is exacerbated by significant claims asserted by Honeywell against certain Garrett subsidiaries under the disputed subordinated asbestos indemnity and the tax matters agreement. These arrangements were a part of an inappropriate capital structure imposed by Honeywell on Garrett as part of its 2018 spin-off that has proven ill-suited to cope with any meaningful challenges at the macroeconomic level, much less those Garrett faces amid a global pandemic. As previously disclosed, payment on the disputed claims by Honeywell has been generally deferred until the second quarter of 2023, but the possibility of the disputed claims being payable in the future - combined with Garrett's high leverage and competitive situation - create a substantial additional overhang on Garrett's balance sheet and impede Garrett's access to capital and its ability to execute its strategy. As a result, Garrett sees a substantial risk that it will not be able to distribute value to its stockholders in the future, despite its strong operating performance and compelling business prospects. Garrett is seeking to address its balance sheet concerns while its core business remains strong in order to preserve the resources necessary to provide exceptional service to its customers, be a reliable partner to its suppliers and other stakeholders, and act as a stable and desirable employer. Garrett has ample liquidity to support its current and future commitments to customers, suppliers, employees and other business partners without interruption, with available cash and undrawn revolver capacity totaling $482 million as of June 30, 2020. Despite the near-term disruption to the automotive industry and the global economy from COVID-19 and the company's over-levered capital structure, Garrett has continued its track record of operational excellence. However, Garrett believes the business must take important steps to maintain its leadership position in light of industry headwinds. In particular, coming out of this crisis, automakers will likely encounter even tougher emission reduction targets and technical challenges that will require new technology to be developed and funded by the major auto suppliers. At the same time, the industry also faces continued uncertainties over the longer-term impact of the pandemic, as well as risk of other similar macroeconomic shocks. We believe that Garrett, with a restructured balance sheet and improved financial flexibility, will be uniquely positioned to bring customers the cutting-edge technologies and required solutions to benefit fully from a global regulatory environment driving future vehicle development. Additionally, Garrett will have the ability to invest to further strengthen its position as a market leader in turbocharger technology and expand its presence in the electric software and automotive software markets. Garrett has not yet determined whether to pursue any balance sheet restructuring alternatives. However, any actions taken by Garrett in relation to liability management may materially reduce the value or trading price of our common stock, dilute existing holders of our common stock by the issuance of equity (whether through conversion of existing liabilities into equity or otherwise), or result in the cancellation of existing common stock. There can be no assurance that recoveries in any restructuring will approximate current trading prices of Garrett's securities."

06:07 EDT PepsiCo announces multi-year premier partnership with UEFA Women's football - PepsiCo said in a release, "Ahead of the UEFA Women's Champions League final on August 30th, PepsiCo has announced its multi-year premier partnership with UEFA Women's football, further strengthening its presence across the elite football landscape. PepsiCo's UEFA Women's football partnership will sit alongside its current multi-year sponsorship of the Men's UEFA Champions League. The five year partnership will see PepsiCo support women's football at all levels through to Summer 2025, with PepsiCo a main partner of the UEFA Women's Champions League, the UEFA Women's EURO, the UEFA Women's Under-19 and Under-17 Championships, and the UEFA Women's Futsal EURO, as well as UEFA's Together #WePlayStrong program, which is aimed at encouraging more girls and women to play football."

06:05 EDT Dycom authorizes new $100M stock repurchase program - Dycom said in a release, "Dycom Industries announced that its board has authorized a new $100 million program to repurchase shares of Dycom's outstanding common stock. Repurchases under the new program are authorized to be made over the next eighteen months in open market purchases or privately-negotiated transactions, including pursuant to a Rule 10b5-1 plan. As of August 26, the Company had 31,839,247 shares of common stock outstanding, excluding the dilutive effect of stock options and unvested restricted stock."

06:04 EDT Royal Bank of Canada reports Q3 provision for credit losses C$675M - The total PCL ratio on loans was 40 bps, down 125 bps from last quarter.

06:01 EDT Piedmont Lithium resumes drilling in Carolina Tin-Spodumene Belt - Piedmont Lithium is pleased to announce the company has resumed drilling on its properties located within the world-class Carolina Tin-Spodumene Belt in North Carolina, USA. The drill program will consist of approximately 5,600 meters. The program's primary objectives are to drill Exploration Target areas on the Core and Central properties, as well as previously untested occurrences of spodumene bearing pegmatite on regional properties.

05:43 EDT Origin Agritech announces commercialization agreement for new corn gene - Origin Agritech said in a release, "Origin Agritech announced that the Company has entered a commercialization agreement with Institute of Plant Protection, or IPP, of the Chinese Academy of Agricultural Sciences, or CAAS, for a new generation insect-resistant GMO corn gene. Origin has been collaborating closely with CAAS for more than 10 years, and IPP supplied Origin with the insect-resistant gene and with technological support. Origin has since taken the gene and created transgenic corn and further went on to validate the efficacy of the insect-resistant gene. Given that the project has cleared this major hurdle, the parties have expanded their collaboration into a commercialization agreement. Under the terms of the agreement, the parties will continue to work together and intend to jointly file for patents on the transgenic corn and other crops created from this gene. Origin will be responsible for obtaining a bio-safety certificate, a key step needed before commercialization in China. Origin will retain exclusive worldwide rights to commercialize all crop seed containing this gene and in return will pay a single-digit percentage of sales royalty to IPP."

04:53 EDT Fluidigm receives Emergency Use Authorization from FDA for Covid-19 test - Fluidigm announced it has received Emergency Use Authorization from the Food and Drug Administration for the Advanta Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus, designed to be run on the Fluidigm Biomark HD microfluidics platform. Because it is saliva-based, the Advanta Dx SARS-CoV-2 RT-PCR Assay does not require collection via nasopharyngeal swab, the company said in a statement. The clinical study associated with the Emergency Use Authorization submission demonstrated 100% agreement between the saliva results from the Advanta Dx SARS-CoV-2 RT-PCR Assay and the results from paired nasopharyngeal samples tested with authorized assays, it added.